The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification.

Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults with Type 2 diabetes. The Control-IQ+ program—now with the added ...

The new type 2 diabetes treatment algorithm consensus statement from the American Association of Clinical Endocrinologists (AACE), running to 48 pages, has been published online and is available for ...

The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.

The US Food and Drug Administration (FDA) has expanded the indication for Tandem Diabetes Care’s Control-IQ+ Technology to include people with type 2 diabetes (T2D). The next-generation Control-IQ+ ...

In addition to BP control, early and intensive management of dyslipidemia is key to preventing macrovascular complications in T2D. The AACE recommends the following lipid targets for patients with T2D ...

Eli Lilly disclosed that retatrutide, its experimental triple hormone receptor agonist, hit the primary and all key secondary ...

Insulet (Nasdaq:PODD) shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes.

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...